Cardiac Ca2+ channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes

Journal Pharmacological Sciences

Volumn 91, Issue 2, 2003, Pages 163-166

  Dohmoto, Hideki ^a   Takahara, Akira ^a   Uneyama, Hisayuki ^a   Yoshimoto, Ryota ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

AH 1058; Cyproheptadine; L type Ca2+ current

Indexed keywords

4 (5H DIBENZO[A,D]CYCLOHEPT 5 YLIDENE) 1 [3 (3 METHOXY 2 NITROPHENYL) 2 PROPENYL]PIPERIDINE; 4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE) 1 [3 (3 METHOXY 2 NITRO)PHENYL 2 PROPENYL]PIPERIDINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CYPROHEPTADINE; DILTIAZEM; NICARDIPINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; GUINEA PIG; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; IC 50; MALE; NONHUMAN; QUANTITATIVE ANALYSIS;

EID: 0038025910     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.91.163     Document Type: Article

References (15)

1. 2+ channel blocker. Cardiovasc Drug Rev 19, 279-296 (2001)
2. Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y, Nakaya H and Yoshimoto R: Effets of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents. J Cardiovasc Pharmacol 33, 625-632 (1999)
3. Tanaka H, Ichikawa T, Matsui S, Okazaki K, Masumiya H, Kawanishi T and Shigenobu K: Calcium channel antagonistic effects of AH-1058, a novel antiarrhythmic drug, on guinea-pig myocardium. Res Commun Mol Pathol Pharmacol 104, 13-21 (1999)
4. 2+ channel blocker, AH-1058, assessed in canine arrhythmia models. Eur J Pharmacol 398, 107-112 (2000)
5. Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R and Hashimoto K: Comprison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations. J Cardiovasc Pharmacol 35, 741-748 (2000)
6. Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R and Hashimoto K: Electrophysiological and cardiohemodynamic effects of a new type of calcium channel blocker AH-1058 assessed by the canine in vivo model. Jpn J Pharmacol 83, 107-112 (2000)
7. 2+ channel blocker AH-1058 in conscious dogs assessed by telemetry. Eur J Pharmacol 413, 101-108 (2001)
8. 2+ channel blocker, in conscious dogs. Jpn J Pharmacol 85, 331-334 (20010
9. Winquist RJ, Siegl PKS, Baskin EP, Bohn DL, Morgan G and Wallace AA: Calcium entry blocker activity of cyproheptadine in isolated cardiovascular preparations. J Pharmacol Exp Ther 230, 103-109 (1984)
10. 2+ channels. Eur J Pharmacol 373, 93-100 (1999)
11. 2+ channel blockades. In Calcium Ion Modulators: The New Wave of Psychotropic Drugs, Edited by Inoue K and Watanabe Y, pp 13 - 23, Harwood Academic Publishers, The Netherlands (1998)
12. Singh PK, Pendse VK and Bhandari DS: Cyproheptadine in ventricular arrhythmias. Indian Heart J 27, 120-126 (1973)
13. Hashimoto K, Haruno A, Matsuzaki T, Sugiyama A and Akiyama K: Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: Which electrophysiological characteristics of drugs are r elated to their effectiveness? Cardiovasc Drug Ther 5, 805-818 (1991)
14. Taira N: Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 59, 24B-29B (1987)
15. Sun J and Triggle DJ: Calcium channel antagonists: Cardiovascular selectivity of action. J Pharmacol Exp Ther 274, 419-426 (1995)